15 results
8-K
EX-10.1
RCEL
AVITA Medical Inc
18 Oct 23
Preliminary commercial revenue of $13.5 million for the third quarter 2023; full year 2023 guidance confirmed
9:07am
in the United States or any other jurisdiction seeking the withdrawal, recall, suspension, import detention or refusal, or seizure of any Product … for more than six months; (ii) there occurs a recall with respect to any Product which could reasonably be expected to result in (A) aggregate liability
10-KT
RCEL
AVITA Medical Inc
28 Feb 22
Annual report (with FYE transition)
4:11pm
of new product launches. In the event our production efforts require a recall or result in an inventory loss, our operating results and financial … impose fines and penalties on the Company and our executives, withdraw or recall our approved product from the market, as well as limit our product
8-K
EX-99.2
RCEL
AVITA Medical Inc
28 Aug 20
AVITA Therapeutics Provides Company Update
11:47am
, and for sales to exceed the U.S.$3.9 million previously reported for the three (3) months ended June 30, 2020.
Recall that in the quarter ended June 30
8-K
EX-99.1
um1rokir1u371o8elii
28 Aug 20
AVITA Therapeutics Provides Company Update
11:47am
10-K
ksj6rqc jh3m
27 Aug 20
Annual report
12:00am
20-F
x06oo6vkknx 54
31 Oct 19
Annual report (foreign)
3:49pm
6-K
EX-99.1
v72arou8g8w80rx6ufa
11 Oct 19
Current report (foreign)
3:37pm
20FR12B/A
79dopz7o56 ua
27 Sep 19
Initial registration of securities (foreign private issuers) (amended)
4:13pm
20FR12B/A
t3zy1i1lt9j
25 Sep 19
Initial registration of securities (foreign private issuers) (amended)
6:07am
20FR12B
gxknvms1
19 Sep 19
Initial registration of securities (foreign private issuers)
4:43pm
DRS/A
gevxnscc
11 Sep 19
Draft registration statement (amended)
12:00am
DRS/A
whn c9t07
23 Aug 19
Draft registration statement (amended)
12:00am
DRS
ijdjr yu5gqrodm2
19 Jul 19
Draft registration statement
12:00am
- Prev
- 1
- Next